New drug melflufen tested in Real-World setting for Tough-to-Treat myeloma
NCT ID NCT07559799
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is observing 50 patients with relapsed or refractory multiple myeloma who are taking melflufen plus dexamethasone as a later-line treatment. The goal is to see how well the drug controls the disease in routine medical practice, outside of a controlled trial. Researchers will track response rates, side effects, and how long patients live without their cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
melphalan flufenamide (melflufen) plus dexamethasone
What this could lead to
If successful, this study could confirm that melflufen helps control advanced multiple myeloma in everyday practice, offering a treatment option for patients who have run out of other choices.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. The drug is already approved, but it may not work for everyone and can cause side effects like low blood counts or infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Praxis für interdisziplinäre Onkologie & Hämatologie
RECRUITINGFreiburg im Breisgau, Germany
Contact